Jefferies says buy this pharmaceutical play, sees more than 100% upside from here

By CNBC | Nov 19, 2024 at 06:24 AM EST

Jefferies analysts see potential for Aclaris Therapeutics' stock to rise further due to recent drug developments. Positive results from BSI-045B treatment for atopic dermatitis could lead to significant gains, with other analysts also bullish on the company's prospects.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.